These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 24775717

  • 1. Current management of advanced and castration resistant prostate cancer.
    Gomella LG, Petrylak DP, Shayegan B.
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [Abstract] [Full Text] [Related]

  • 2. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 3. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [Abstract] [Full Text] [Related]

  • 4. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [Abstract] [Full Text] [Related]

  • 5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Apr; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 7. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F.
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [Abstract] [Full Text] [Related]

  • 8. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK, Abughaban A, Aragon-Ching JB.
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [Abstract] [Full Text] [Related]

  • 9. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [Abstract] [Full Text] [Related]

  • 10. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R.
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [Abstract] [Full Text] [Related]

  • 11. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H, Garcia JA.
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [Abstract] [Full Text] [Related]

  • 12. Current state of castration-resistant prostate cancer.
    Petrylak DP.
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
    [Abstract] [Full Text] [Related]

  • 13. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.
    J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
    [Abstract] [Full Text] [Related]

  • 14. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ, Zhang J.
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [Abstract] [Full Text] [Related]

  • 15. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [Abstract] [Full Text] [Related]

  • 16. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
    Akaza H.
    Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
    [Abstract] [Full Text] [Related]

  • 17. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 18. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA, Dzik C, Rathkopf D, Scher HI.
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [Abstract] [Full Text] [Related]

  • 19. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 20. The utility of prostate-specific antigen in the management of advanced prostate cancer.
    Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.
    BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.